Semarion

About:

Semarion leverages microfabrication technology to build smart materials and develop novel cell assaying applications.

Top Investors: Martlet Capital, Parkwalk Advisors, University of Cambridge Enterprise, Start Codon

Description:

Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. Semarion combines microchip industry materials and techniques engineering and cell biology to tackle unmet drug screening needs.

Total Funding Amount:

2.39M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2018-01-01

Contact Email:

info(AT)semarion.com

Founders:

Number of Employees:

1-10

Last Funding Date:

2022-02-22

IPO Status:

Private

Industries: